Triple negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers and has the worst survival rate. Immunotherapy is a new treatment option but resistance is frequent. We have demonstrated that TNF induces trastuzumab resistance through mucin 4 (MUC4) upregulation and it is ...
2015 Apr 文章题目是:Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer 主要是考虑到TNBC是异质性较大的一种乳腺癌,而且预后非常差,所以临床用药指导急需对TNBC本身更加细致的分类,研究团队通过贝勒医学院分两次 收集了 198个TNBC病人, (discovery set: n=84; ...
12月份第2周(总第46周)探索TNBC新的亚型分类 发表于:Clin Cancer Res. 2015 Apr 文章题目是:Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer 主要是考虑到TNBC是异质性较大的一种乳腺癌,而且预后非常差,所以临床用药指导急需对TNBC本身更加细致的分类,研究团队...
Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triplenegative breast cancer (TNBC) Background:Locally advanced unresectable or metastatic TNBC is highly aggressive and has a poor prognosis. Ivonescimab, a tetravalent bispecific a...
in development for the treatment of solid tumors. We conducted a Phase Ib/II study of PM8002/BNT327 in combination with nab-paclitaxel in pts with locally advanced or metastatic triple-negative breast cancer (LA/mTNBC) in China. We provide updated results including interim overall survival (OS...
Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients ...
Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.
Heretofore we haven’t had anything first-line that would be preferred over something else, so we didn’t have any survival advantage. So take your pick [in the] first line, right? I mean, the National Comprehensive Cancer Network [NCCN] says sequential single agents, you ...
Fudan University Shanghai Cancer Center TNBC umbrella CI: Confidence interval EGFR: Epidermal growth factor receptor RFS: Relapse-free survival PFS: Progression-free survival OS: Overall survival CR: Complete response PR: Partial response SD: Stable disease CBR: Clinical benefit rate DF...
Positive efficacy data have halted the confirmatory phase III ASCENT study exploring sacituzumab govitecan in patients with metastatic triple-negative breast cancer.